| 1 |
35063965 | Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. | 2022 Jan 21 |
1 |
| 2 |
35381683 | [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report]. | 2022 Feb 14 |
1 |
| 3 |
25643589 | Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. | 2015 Apr |
2 |
| 4 |
22230298 | Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. | 2012 May |
1 |
| 5 |
21750085 | Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. | 2011 Oct |
1 |
| 6 |
19776758 | Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. | 2010 Jan |
1 |